Combined use of CA 19-9 and CEMIP significantly increased the sensitivity and specificity in discriminating not only patients with all stage pancreatic cancer but also patients with stage I/II pancreatic cancer from healthy individuals. Here, CEMIP is linked to pancreatic neoplasm.